Need a mesothelioma lawyer? We will fight for you!
› $150,000,000 verdict in personal injury case
Women who took Wyeth’s hormone replacement therapy (HRT) Prempro at least five years are at greater risk of dying from non-small cell lung cancer, according to a recent study presented at an American Society of Clinical Oncology meeting.
The Food and Drug Administration (FDA) is expected to issue a warming to doctors about an increased risk of the recurrence of breast cancer with patients taking both the breast cancer drug tamoxifen and select antidepressants, according to a study released last week at the American Society of Clinical Oncology’s annual meeting.
Women on hormone replacement therapy (HRT) who have no family history of breast cancer have the same risk of developing breast cancer as women with a family history who are on HRT, according to a University of Rochester Medical Center Study.
The more than 2 million baby-boomer women who are approaching menopause may find themselves in a precarious position when it comes to handling hot flashes and mood swings. Should they risk the threat of breast cancer from use of hormone replacement therapy, or simply suffer through the agonizing symptoms? According to Forbes, new and detailed research offers women the opportunity to make a more educated decision.
A new study published this week in the New England Journal of Medicine suggests a sudden decrease in breast cancer in several countries worldwide is likely linked to the 2002 Women’s Health Initiative (WHI) finding that hormone replacement therapy (HRT) after menopause can dramatically increase a woman’s risk of breast cancer and other serious health problems, the Wall Street Journal reports.
A federal study revealed that the pharmaceutical company Wyeth paid ghostwriters to write articles for medical journals that were favorable to the drug company’s hormone replacement therapy (HRT) Prempro, even after the drug was found to raise a woman’s risk for breast cancer, according to the New York Times.
Hormone replacement therapy (HRT) and its link to breast cancer and other serious conditions continue to make headlines. This week, U.S. News & World Report announced that women who take HRT and then get breast cancer are at lower risk of dying from their disease, according to a new study by the University of California-Irvine.
A study in the Journal of the American Medical Association (JAMA) reveals that women who took hormone replacement therapy (HRT) face an increased risk of cancer several years after stopping the treatment, according to an NPR report.
Overweight women suffer more hot flashes during menopause than women who maintain a normal weight, according to the Hartford Courant. The news story references a study published by the American Journal of Epidemiology that debunks an earlier belief that menopausal women who were heavier experienced fewer hot flashes than thin women.
In the 1960s, a New York gynecologist wrote a book called “Feminine Forever,” in which he recommended estrogen for menopause, stating that women on the hormone replacement drug “will be much more pleasant to live with and will not become dull and unattractive.”
Wyeth Pharmaceuticals caught wind of the book and its author’s claims that estrogen reduced a woman’s risk for both breast and genital cancers, and began distributing the book to physicians across the country. Soon after, sales of Wyeth’s HRT drug Premarin took off, growing to more than 30 million prescriptions each year.
![[ Beasley Allen Law Firm Logo ]](http://www.hrt-legal.com/wp-content/themes/system-unity/images/logo.png){kind=logo}
